A carregar...
Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
Although adults with B-cell acute lymphoblastic leukemia (B-ALL) achieve high complete remission (CR) rates following treatment with intensive multi-agent chemotherapy regimens, up to two-thirds of these patients eventually relapse. Unfortunately, adults with relapsed or refractory (R/R) B-ALL have...
Na minha lista:
| Publicado no: | Blood Lymphat Cancer |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7648528/ https://ncbi.nlm.nih.gov/pubmed/33173373 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BLCTT.S223894 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|